Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.61 |
| ▸ | MAOB | P27338 | 8/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | CALML3 | P27482 | 1/20 | 0.51 |
| ▸ | SDHA | P31040 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 10/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11969566 | 1.00 | MAOA (0.61) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL13428711 | 0.92 | MAOA (0.61) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL11983070 | 0.92 | MAOA (0.61) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL13428713 | 0.92 | MAOA (0.60) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL11968992 | 0.92 | MAOA (0.60) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL11968979 | 0.91 | MAOA (0.65) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL11968998 | 0.90 | MAOA (0.47) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL13428714 | 0.90 | MAOA (0.47) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL11968944 | 0.90 | MAOA (0.76) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL13428762 | 0.89 | MAOA (0.59) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010036000-A2 | NOVEL OXAZOLIDINONE DERIVATIVES WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AND PHARMACEUTICAL COMPOSITIONS THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2010-04-01 | — | — | WO | disclosed |